Podcast Highlights

Picking on Pruritus as a Problematic Clinical Biomarker in Autoimmune Connective Tissue Diseases

By December 29, 2019January 29th, 2020No Comments

Pruritus is the worst – plain and simple. However we have only just scratched the surface with respect to why it happens in a multitude of clinical scenarios and what it could be telling us other then “SCRATCH ME.”

In this edition of the JDD Podcast, Dr. Gideon Smith, assistant professor of dermatology at Harvard Medical school, Vice Chair for Clinical Affairs in Dermatology, and Director of the Connective Tissue Diseases Clinic and Fellowship joins us to pick apart his recent study in the JDD October 2019 edition, Characterizing Pruritus in Autoimmune Connective Tissue Diseases.

At the conclusion of the eight-week treatment, the rate of success was significantly higher for patients randomized  to once-daily treatment with halobetasol 0.01% lotion compared with vehicle-treated controls (P<.001 for both comparisons).

Tune in to learn how not all itch is created equal in the autoimmune connective tissue world. Determine what questions can help guide management and therapy selection. Hear how to connect with rheumatology to forge a long lasting partnership, just like itchy and scratchy.

Listen Now

You May Also Like

Featured ArticlesLatest NewsPodcast HighlightsThe Latest
May 2, 2025

Thin Skinned: Topical Steroid Safety and Legal Landmines

Just put some salve on it" sounds so innocuous one could follow up with, "what could possibly go wrong?" Never ask that. Yes, our skin is our living breathing barrier…
Featured ArticlesFeatured PodcastPodcast HighlightsThe Latest
April 3, 2025

From Rags to Itches: The Evolution of Topical and Systemic Options for Pruritus

Featured Podcast Life's an itch sometimes….am I right? Pruritus can pick apart the fabric of one's life as both a symptom of a primary skin disease or even as a…
Even in a world of exponentially expanding systemic options both on and off label, one fact remains: topical therapy is ALWAYS on the menu. With an unprecedented array of nonsteroidal options, understanding the underpinnings to both use them for their intended purpose, but even more fun, OOOOOOFFFFFF LLLLLLAAAAABBBBEEEELLLL (clearly a fan of off label), is paramount to patient outcomes. Be not overwhelmed I say, as the bench to bedside badass Dr. Christopher Bunick is here for all your on and off label needs. Take a break from the typical Tuesday with a topical translational deep dive into the tantalizing options as host Dr. Adam Friedman tees off with Dr. Bunick for what is certain to be a “tough” (as the kids say) podcast.Featured ArticlesFeatured PodcastPodcast HighlightsThe Latest
March 31, 2025

Touching on Tailored Topical for Tons of Tough Treatment Tchallenges

Featured Podcast Even in a world of exponentially expanding systemic options both on and off label, one fact remains: topical therapy is ALWAYS on the menu. With an unprecedented array…